Robert Hart, MD
Family Medicine · Hickory, NCNPI 1326044504
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $969 and has fallen 56.2% since, to $424 in 2025. Among family medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$849
- Lilly USA, LLC$779
- Novo Nordisk$599
- Johnson & Johnson$400
- GSK$206
- AbbVie$190
- plus $2K from 33 others
Across 79 payments — averaging $7988.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$238K
- Orasure Technologies Inc.$124K
- Pfizer$120K
- Genentech, Inc.$82K
- F. Hoffmann-la Roche AG$39K
- Boehringer Ingelheim Canada Ltd.ltee$25K
- plus $2K from 1 others
What the payments were for
- Food & beverage$5,11299%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $849 |
| Lilly USA, LLC | 47 | $779 |
| Novo Nordisk | 44 | $599 |
| Johnson & Johnson | 28 | $400 |
| GSK | 11 | $206 |
| AbbVie | 10 | $190 |
| Merck | 13 | $189 |
| Amarin Pharma, Inc. | 11 | $163 |
| Bayer | 8 | $155 |
| Astellas Pharma US Inc | 8 | $151 |
| Abbott | 6 | $134 |
| Idorsia Pharmaceuticals US Inc | 6 | $131 |
| Globus Medical | 1 | $115 |
| Phathom Pharmaceuticals, Inc. | 7 | $108 |
| Sumitomo Pharma America, Inc. | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $92 |
| Boehringer Ingelheim | 4 | $82 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| Dexcom, Inc. | 2 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Pfizer | 3 | $47 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Novartis | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 3 | $42 |
| Exact Sciences | 2 | $40 |
| Mylan Specialty L.p. | 2 | $35 |
| Zyla Life Sciences, Inc. | 2 | $31 |
| Amgen | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Inari Medical, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Cranial Technologies, Inc | 1 | $12 |
| Tris Pharma Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quartex$115
How this compares
$5,146 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 63 | $69,426 |
| EliquisApixaban | 66 | $45,103 |
| RybelsusSemaglutide | 11 | $26,888 |
| InvokanaCanagliflozin | 27 | $23,439 |
| FarxigaDapagliflozin Propanediol | 26 | $17,923 |
| XareltoRivaroxaban | 13 | $12,185 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 44 | $9,735 |
| TradjentaLinagliptin | 11 | $5,252 |
| Lisdexamfetamine Dimesylate | 11 | $4,318 |
| Atorvastatin Calcium | 340 | $3,153 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,057 |
| Testosterone Cypionate | 39 | $2,375 |
| Tamsulosin Hcl | 126 | $2,041 |
| Metformin Hcl | 266 | $1,988 |
| Levothyroxine Sodium | 234 | $1,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $82 | $74,67774 claims |
| PfizerEliquis | $47 | $45,10366 claims |
| Johnson & JohnsonInvokana, Xarelto | $400 | $35,62440 claims |
| Novo NordiskRybelsus | $599 | $26,88811 claims |
| AstraZenecaFarxiga | $849 | $17,92326 claims |
| GSKShingrix | $206 | $9,73544 claims |
| AbbVieSynthroid | $190 | $1,63919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Hickory
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.